Search

Evolutionary immune system upgradation is done by all living organism to survive from the invading pathogens. Insects has a strong defense system comprising of anatomical barrier, humoral antimicrobial peptide (AMP) production and cellular immune components. Locusta migratoria (L. migratoria) is an agricultural pest insect migrating long distance might encounter distinct pathogens. Owing to this, we aimed in identifying AMPs present in the L. migratoria and elucidate the antimicrobial activity. The migratory locust was immunized with Escherichia coli, Staphylococcus aureus, Candida albicans mixture, then RNA was isolated and sequenced. The L. migratoria transcriptome was de novo assembled using trinity and screened for AMPs propensity specifically molecular and aggregation properties. The novelty is tested by blasting in known AMP databases. Finally, obtained novel putative AMPs were then tested for antimicrobial and hemolytic activity. The prediction resulted in 3,524 putative AMPs which was further screened down to ten AMPs for final testing. Two peptides showing promising antimicrobial effects were obtained. All the analyzed peptides showed no hemolysis confirms its non-toxicity. Thus, our peptides could be promising drug candidate and can be used as an alternative to antibacterial or antifungal therapy with further validations.

Background Coumarin plays a vital role in drug discovery process due to its diverse biologically active components. Recently, coumarin derivatives are paying attention to treat various diseases including cancer. The effect of coumarin derivatives on gastric cancer is not well established although gastric cancer being the fourth leading cancer. Therefore, we attempt to study the effect of styrene substituted biscoumarin (SSBC) to induce apoptosis and inhibit cancer proliferation using in silico and in vitro approaches. Methods We performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to identify the anti-proliferative activity of SSBC in stomach cancer cell lines (AGS) and toxicity of the compared was also assessed using lung normal cell lines (L-132 and MRC-5). A docking study was carried out between anti-apoptotic protein (BCL2) and SSBC compound. Furthermore, we analyzed the drug likeliness by screening pharmacological properties (ADME) and biological activity of SSBC by performing spectrum prediction analysis (PASS). The apoptotic effect of SSBC in AGS cell lines were detected using flow cytometry (FACS), Hoechst staining and DAPI/PI staining. Later, the regulation of apoptotic pathway by SSBC was also confirmed by qRT-PCR and western blotting analysis. Results The inhibition concentration (IC50) of SSBC was assayed against AGS and lung normal cell lines (L-132 and MRC-5). The IC50 value of SSBC toward AGS, L -132 and MRC-5 was 4.56, 268 and 285 μg/ml, respectively. In silico analysis predicted SSBC could bind to the active site of BH3 domain of anti-apoptotic protein and thus resulted in apoptotic mediated cell death. ADME prediction of SSBC exhibit strong binding capacity of 99.08% and showed absorption rate about 95.57% in the intestine. In addition, biological activity of SSBC was also predicted using PASS program and we found SSBC exhibit high activity for various cancer related protein expression including apoptosis pathway proteins such as caspase 3 stimulant, apoptosis agonist. Furthermore, apoptosis of AGS was also assessed using Hoechst staining, DAPI/PI analysis, flow-cytometric analysis, qRT-PCR and western blot analysis. Conclusion Our study denotes that SSBC could be very effective against AGS by inducing apoptosis through intrinsic pathway and recommended for in vivo and human trials.

The purpose of this study was to evaluate the anticancer efficacy of interferon β in combination with low dose of cisplatin on human cervical cancer progression, as well as its principal action mechanism. The combination treatment synergistically potentiated the effect of interferon β on cell growth inhibition and DNA damage on HeLa cells by repressing NF-κB/p-Akt signaling. Synergistic targeting of these pathways has a therapeutic potential. Further, the combination treatment ameliorated the expression of pro-apoptotic Bax, and decreased the expression of anti-apoptotic protein Bcl-2. Additionally, the expression of active PARP was significantly increased and MMP-9 level was decreased in combination group as compared to the expression seen for the treatment with interferon β or cisplatin alone. Results demonstrate that the synergistic inhibitory effects of interferon β and low dose of cisplatin on human cervical cancer cells and also suggest that the inhibition of NF-κB/p-Akt signaling pathway plays a critical role in the anticancer effects of combination treatment along with the induction of PARP. Therefore, the combination of interferon β and cisplatin may be a useful treatment for human cervical cancer, with a greater effectiveness than other treatments.